Table 1.
Characteristics of women with hormone-receptor positive breast cancer who received aromatase inhibitors (AI) and genotype data in the Pathways Study.
| Variable | n (%) |
|---|---|
| Age at breast cancer diagnosis, median (range), years | 63 (28–94) |
| Age at breast cancer diagnosis, years, n (%) | |
| <50 | 69 (3.6) |
| 50–59 | 551 (28.6) |
| 60–69 | 815 (42.3) |
| ≥70 | 492 (25.5) |
| Menopausal status at breast cancer diagnosis | |
| Premenopausal | 123 (6.4) |
| Postmenopausal | 1804 (93.6) |
| Race/ethnicity | |
| White | 1499 (77.8) |
| Black | 115 (6.0) |
| Asian | 170 (8.8) |
| Hispanic | 143 (7.4) |
| Body mass index at breast cancer diagnosis, median (range), kg/m2 | 27.9 (15.6–62.0) |
| Body mass index at breast cancer diagnosis, kg/m2 | |
| <25 kg/m2 | 532 (27.6) |
| 25–29.9 kg/m2 | 618 (32.1) |
| ≥30 kg/m2 | 777 (40.3) |
| AJCC stage | |
| I | 1058 (54.9) |
| II | 656 (34.0) |
| III | 184 (9.6) |
| IV | 29 (1.5) |
| Breast cancer treatment | |
| Chemotherapy | 217 (11.3) |
| Radiation therapy | 798 (41.4) |
| Both | 508 (26.4) |
| None | 404 (21.0) |
| AI treatment length | |
| ≤2 years | 558 (29.0) |
| 2.1–4 years | 322 (16.7) |
| 4.1–5 years | 644 (33.5) |
| >5 years | 401 (20.8) |
| Bisphosphonate use after AI initiation | |
| No | 1357 (70.4) |
| Yes | 570 (29.6) |
| Osteoporosis prior to breast cancer diagnosis | |
| No | 1779 (92.3) |
| <5 years | 104 (5.4) |
| ≥5 years | 44 (2.3) |
| Major osteoporotic fracture prior to breast cancer diagnosis | |
| No | 1836 (95.3) |
| <5 years | 57 (3.0) |
| ≥5 years | 34 (1.8) |
| Baseline BMD at the spine, median (range) | 0.99 (0.55, 1.68) |
| Baseline BMD at the hip, median (range) | 0.89 (0.45, 1.44) |
| Baseline BMD at the femoral neck, median (range) | 0.73 (0.38, 1.15) |